XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

François Ghiringhelli, Principal Investigator of the TASKIN study and Director of the Oncology Department at Centre Georges-François Leclerc

“Patients with refractory metastatic colorectal cancer face severe therapeutic limitations and poor survival outcomes. Meeting our pre-specified primary milestone provides compelling evidence that targeting IL-1α plays a meaningful role in tumor biology. Most striking is the magnitude of benefit observed in right-sided colorectal cancers, which has been a historically aggressive disease subset with high unmet medical need. The alignment between this pronounced clinical survival advantage and elevated basal IL-1α tumor expression offers a clear biological rationale for this therapy.”

Sushma Shivaswamy, Chief Scientific Officer and Interim Chief Executive Officer of XBiotech

“We are deeply grateful to Professor Ghiringhelli, the team at Centre Georges-François Leclerc, the French National Cancer Institute, and all the participating patients for advancing this important trial. By uncovering a biomarker-anchored patient population in right-sided disease that derives substantial clinical benefit from vilamakitug, TASKIN provides a focused and validated direction as we advance vilamakitug toward registrational clinical development.”